Can a radioactive drug shrink Slow-Growing tumours?
NCT ID NCT01876771
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial tests whether a radioactive drug called Lu-DOTA-TATE can shrink or slow neuroendocrine tumours — rare, slow-growing cancers that often spread before diagnosis. The drug delivers radiation directly to tumour cells that have a specific receptor on their surface. Researchers are measuring tumour response, survival, side effects, and quality of life in about 400 patients aged 14 to 90.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a radioactive drug called Lu-DOTA-TATE (lutetium-177 dotatate) that targets tumour cells
- What this could lead to
- If it works, this could provide a publicly funded treatment option for neuroendocrine tumours in Alberta, potentially improving survival and quality of life.
- What could go wrong
- This is a single-arm, open-label study, so results may be less reliable than a blinded, controlled trial. The drug can cause side effects like blood cell changes and kidney stress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NEUROENDOCRINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scan bonus: cancer PET may spot inflammation
- New hope for rare cancers: experimental drug ADCT-701 enters human trials
- New study aims to unlock secrets of lung cancer drug through blood tests
- Can a simple blood test predict cancer risk from radiation therapy?
- Promising new combo aims to extend life in rare, Tough-to-Treat cancer
- New drug duo targets hard-to-treat cancers in early trial